IBM — International Business Machines Corporation

Sentiment is mixed-to-neutral. Q2 2026 revenue of $17.16B grew only ~1% YoY and missed consensus by roughly 4%, breaking a five-quarter streak of beats, but management kept full-year 4-5% constant-currency guidance. Sell-side consensus is a moderate Buy with a $255.92 average target, but the stock remains below its 50- and 200-day moving averages, so the tape is not confirming the bullish narrative yet.

Revenue growth accelerated through 2025 (Q3 2025 +9.1% YoY, Q4 2025 +12.2% YoY, Q1 2026 +9.5% YoY) but collapsed to +1.1% YoY in Q2 2026. That is a real deceleration, though not yet evidence of a structural decline: TTM free cash flow through Q2 2026 was about $13.6B, up ~15% versus the prior four quarters, and Q2 operating cash flow rose 53% YoY. Operating margin fell to 15.2% in Q2 2026 from 18.2% a year earlier, though it ticked up sequentially from 13.9% in Q1 2026. The Q4 2025 net income spike to $5.6B looks flattered by one-offs, so I would not extrapolate the trailing EPS growth rate.

At $238.79, the trailing P/E is 20.9x and forward P/E is about 19.4x on next-fiscal-year EPS of $12.31. That is far below IBM's 5-year average P/E of 35.6x, but that average was inflated by earlier depressed earnings. Price-to-sales of 3.26x is above the 5-year average of 2.79x, so the market is paying up for the software/AI mix. Overall, valuation is fair: not cheap enough to ignore the growth stumble, not expensive enough to be a red flag.

The price is discounting a slow-growth, high-cash-flow compounder and is not giving credit for an AI-led re-acceleration. If Q2's late-quarter deal delays were just timing and IBM delivers its 4-5% constant-currency growth guidance, EPS estimates hold and the stock can drift toward the $255-265 analyst target zone. If delays persist into Q3, estimates get cut and the forward multiple mechanically rises even as the stock falls — the apparent value would be a trap. The tell is Q3 revenue growth: re-acceleration above ~4% re-rates the stock; another 1-2% print keeps it rangebound.

As of 2026-08-27, RSI(14) was 52.7 — neutral, with no overbought or oversold signal. Price was 2.1% above the 20-day SMA but 2.3% below the 50-day and 9.7% below the 200-day, so the intermediate-term trend is still down despite the recent bounce. The near-term range is roughly $230 support to ~$244 resistance at the 50-day; a close above $244 would signal trend repair, while a break below $230 opens a retest of the $199 low.

• Elevated interest rates make IBM's 2.85% dividend and FCF stability relatively more attractive, but also pressure the multiple on lower-growth tech.
• Enterprise AI spending is shifting from proof-of-concept to production; IBM's $12.5B+ gen-AI book is an opportunity only if it converts to actual software/consulting revenue.
• Discretionary IT services/consulting budgets remain soft, which directly hit Q2 revenue and operating margins.
• Hybrid cloud and mainframe refresh cycles create lumpiness; the new Z dual-architecture (IBM+Arm) is a product cycle catalyst, but timing is hard to predict.
• Currency moves matter because IBM guides on constant-currency; a stronger dollar can make reported results look worse than underlying demand.

• Q3 2026 earnings on October 21, 2026 — the main test of whether Q2 deal delays were a blip or a trend.
• Conversion of the $12.5B+ generative-AI book into recognized software, SaaS ACV, and consulting revenue.
• Mainframe/Red Hat product cycle, including the new IBM Z dual-architecture processor with Arm.
• HRL Laboratories acquisition integration in quantum and advanced materials.

• Q2's late-quarter deal delays become structural, pushing 2026 growth below management's 4-5% constant-currency guidance.
• Consulting/IT services margin compression as AI commoditizes parts of delivery.
• Balance sheet leverage: long-term debt of $56.2B, debt-to-equity of 1.9x, and current ratio of 0.79 leave limited financial flexibility if rates stay high or cash flow dips.
• Price-to-sales above its own 5-year average means a growth disappointment could trigger multiple compression.

IBM is a fair-value, income-oriented cash-flow stock, not a high-growth re-rating story at $238.79. Free cash flow is growing, the dividend is well covered, and the AI pipeline is real, but the Q2 revenue miss and weak intermediate-term trend argue against chasing strength. For a patient investor, it is a reasonable hold/add on weakness; for a growth investor, there is no urgency.

Calculated by applying a 21.0x forward P/E to consensus next-fiscal-year EPS of $12.31. The 21x multiple is a conservative discount to IBM's 5-year average P/E of 35.6x, a modest premium to the current ~19.4x forward P/E, and is supported by ~$13.6B TTM FCF, negative accruals, 17.9% TTM operating margin, and a 2.85% dividend yield.